Odyssey Endes For Quest for Nasdaq, pulling the IPO software after almost 5 months

Treatment of Odyssey Withdraw Its application to publiclymid IPO Biotech Market with the basis to stop.

The immune biotech does not give specific reasons for walking back its IPO map, not the best of the company. “

Odyssey First File for IPO in January Along with a friend Massachusetts Ctiosta Arrapututics. The last company encouraged the offer through its offer, landing on the Nasdaq floor $ 219.2 million in February. On the other hand, the Odyssey at that time does not determine a detailed goals.

After the explosion of initial activity to start the year, IPos has Slow down a lot. Treatment Maze Maze has opened 2025 IPO class in early January, eventually raise 140 million to develop drugs in chronic kidney. Since launch on Nasdaq, the maze shares fell 20%.

Similar fate have been waiting more aspects of the biotechs that are tracked in the footsteps of the maze. For example, for example, fell 34% since its IPO, while Aardvark arrapututics, which Filed for IPO in FebruaryIt was settled 12%.

However, one company feels what is more likely to make trends, which is a star growing in local area. Biotech opened Nasdaq auction NASDAQ in January with a Target to fund $ 289 million, Eventually collecting More than $ 316 million At the beginning of February. A Package of positive reading Helped bolster shares of the company.

Odyssey, meanwhile, we are looking forward to public market leverage to develop medications in the source. “Company Leader Is a small molecule inhibitor that makes stimulating in the bottom movement of a comfortable player. Applicants, issue Ad-07656, now in the course of I I have developed for wounds and colitis disease and disease of Crohn. Odyssey Present Information that the American Science Sciences of America in 2024 in October 2024 in support of operation mechanisms

Aside from OD-07656, Odyssey also works on protein medicines for protein treatment for simple education.